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Abstract 
Background 
Melanoma is the most deadly form of skin cancer. Expression of oncogenic BRAF or NRAS, 
which are frequently mutated in human melanomas, promote the formation of nevi but are 
not sufficient for tumorigenesis. Even with germline mutated p53, these engineered 
melanomas present with variable onset and pathology, implicating additional somatic 
mutations in a multi-hit tumorigenic process. 
Results 
To decipher the genetics of these melanomas, we sequence the protein coding exons of 53 
primary melanomas generated from several BRAFV600E or NRASQ61K driven transgenic 
zebrafish lines. We find that engineered zebrafish melanomas show an overall low mutation 
burden, which has a strong, inverse association with the number of initiating germline 
drivers. Although tumors reveal distinct mutation spectrums, they show mostly C > T 
transitions without UV light exposure, and enrichment of mutations in melanogenesis, p53 
and MAPK signaling. Importantly, a recurrent amplification occurring with pre-configured 
drivers BRAFV600E and p53-/- suggests a novel path of BRAF cooperativity through the protein 
kinase A pathway. 
Conclusion 
This is the first analysis of a melanoma mutational landscape in the absence of UV light, 
where tumors manifest with remarkably low mutation burden and high heterogeneity. 
Genotype specific amplification of protein kinase A in cooperation with BRAF and p53 
mutation suggests the involvement of melanogenesis in these tumors. This work is important 
for defining the spectrum of events in BRAF or NRAS driven melanoma in the absence of UV 
light, and for informed exploitation of models such as transgenic zebrafish to better 
understand mechanisms leading to human melanoma formation. 
Background 
Melanoma is a form of skin cancer known for its therapeutic resistance, aggressiveness and 
late metastatic manifestation [1]. Activating mutations in BRAF (V600E) or NRAS (Q61K) 
are collectively found in approximately 60% of human melanomas and result in the 
constitutive signaling of the mitogen-activated protein kinase (MAPK) pathway [2,3]. 
Although studies have shown a clear dependence of tumour growth on MAPK signaling, 
most nevi with BRAFV600E or NRASQ61K mutations remain benign for decades [4]. In 
zebrafish, expression of human BRAFV600E (BRAF) or NRASQ61k (NRAS) in melanocytes 
results in the growth of pigmented, nevus-like lesions that also rarely progress to melanoma. 
Invasive melanomas develop in these transgenic zebrafish only in combination with 
engineered loss of p53 function [5,6], and yet manifest with variable onset and penetrance, 
strongly suggesting that these drivers are not sufficient for malignant melanoma formation 
and the requirement for additional unknown, somatic events. 
Recent analyses of the genomes and exomes of human melanoma have resulted in the 
identification of new mutations that are likely to contribute to the disease formation or 
survival [7-11]. One confounding aspect of discriminating drivers in melanoma is the 
elevated background mutation burden due to UV mutagenesis, although new algorithms have 
been developed to refine this analysis [10]. We sought to build upon these studies through a 
focused analysis of a set of engineered melanomas, to determine the spectrum of mutations in 
the absence of UV light and to interrogate the role of BRAF, NRAS and p53 in melanoma in 
transgenic zebrafish. Specifically, we used targeted exon enrichment and Illumina sequencing 
to generate exome and copy-number alteration data for 53 samples consisting of 38 BRAF 
driven and 15 NRAS driven primary zebrafish melanomas and cell lines with additional 
perturbations. A detailed examination of the spectrum of somatic point mutations, insertions, 
deletions and amplifications is presented. Our analysis reveals striking genetic heterogeneity, 
genotype specific mutation patterns and a potential novel path to BRAF driven 
tumourigenesis, providing insights into the events important for cooperation with BRAF and 
NRAS in the context of low mutation burden. 
Results and discussion 
Study set and sequencing overview 
We collected matched zebrafish melanoma and normal tissue from 53 transgenic zebrafish 
harbouring tissue-specific oncogenic alleles of human BRAF and NRAS under a melanocyte-
specific (mitfa) promoter [5,6] (Table 1, Additional file 1: Table S1, Figure 1). Specifically, 
38 fish expressed oncogenic BRAFV600E (BRAF) and 15 expressed oncogenic NRASQ61K 
(NRAS). The majority of samples (33 BRAF and 14 NRAS individuals) carried at least one 
germline, mutant p53 allele (p53M214K [12]). While p53 itself has not traditionally been 
considered to be a major tumour suppressor in melanoma development, inactivation of 
CDKN2A/p16 is associated with loss of p53 activity [13]. Further, the high mutation load in 
p53 and its pathway components in melanoma also underscores its importance [10]. Four 
BRAF fish harboured a germline temperature sensitive hypomorphic allele of mitfa (mitfavc7) 
[14,15]. Of BRAF individuals with aberrant p53, 38 had additional mutant germline alleles in 
mitfa-/- (known as nacre-/-) [16], ptenahu1864 +/- [17] or mitfavc7 [14,15]. Transgenic individuals 
with BRAF;p53-/-;mitfa-/- were manipulated with a miniCoopR shuttle vector system [18], 
consisting of somatic mosaic rescue of MITF expression in melanocytes along with SETDB1 
[18] and transcription factors KROX20, FOXD3 or OCT6, the biology and oncogenicity of 
which are being investigated independently. 
  
Table 1 Study set overview 
Genotype Samples 
mitf:BRAFV600E 1 
mitf:BRAFV600E;p53+/- 2 
mitf:BRAFV600E;p53+/-; ptenahu1874 +/- 1 
mitf:BRAFV600E;mitfvc7+/+; 4 
mitf:BRAFV600E;mitfvc7+/+;p53+/- 4 
mitf:BRAFV600E; p53-/-;mitf-/-;mitf:MITF 6 
mitf:BRAFV600E;p53-/-;mitf-/-;mitf:MITF;mitf:foxd3 4 
mitf:BRAFV600E;p53-/-;mitf-/-;mitf:MITF;mitf:krox20 12 
mitf:BRAFV600E;p53-/-;mitf-/-
;mitf:MITF;mitf:krox20/foxd3/OCT6 * 
1 
mitf:BRAFV600E;p53-/-;mitf-/-;mitf:MITF;mitf:SETDB1 1 
mitf:BRAFV600E;p53-/-;mitf-/-;mitf:MITF;mitf:EGFP 1 
mitf:NRAS1Q61K 2 
mitf:NRAS1Q61K;p53-/- 5 
mitf:NRAS1Q61K;p53+/- 4 
mitf:NRAS1Q61K;p53+/-;rps29+/- 5 
Total 53 
Note that for asterisk (*) labeled tumours, the genes krox20, foxd3 and OCT6 were each expressed on separate plasmids. 
Figure 1 Examples of zebrafish melanomas. BRAF (left panel) and NRAS (right panel) 
driven zebrafish melanomas in a p53-/- background, with specimen example (top panel) and 
histology (bottom panel). 
To analyze coding regions of the zebrafish genome, we performed targeted exome capture on 
tumour and normal DNA followed by 75 base paired-end Illumina (HiSeq) sequencing 
(European Nucleotide Archive accessions ERP003701, ERP003702). The bait set covered all 
protein coding genes, 3’UTRs and 5’UTRs of the Zv8 and later Zv9 genome for a combined 
coverage of 60 MB. A total of 2,309 Gb of sequencing was generated, averaging 
approximately 21.8 Gb per sample (Additional file 1: Table S2). 
Because of the complexity and diversity of the zebrafish genome [19], we addressed the 
sensitivity and precision of applying the CaVEMan substitution calling algorithm [20] to 
zebrafish through two analyses: variant calling simulations and comparison to additional 
callers. In the first instance, we measured the performance of CaVEMan in simulated 
zebrafish tumour and normal genomes, which showed that the algorithm detected somatic 
substitutions with both high sensitivity and precision within these conditions (Additional file 
2: Figure S1, Supplementary text in Additional file 3). We next employed CaVEMan for 
substitution calling on the zebrafish melanoma study set. Through manual inspection of each 
variant, we determined that a large proportion of these substitutions were false positives 
(57%, Additional file 2: Figure S2a), many due to germline variants that had been missed by 
the algorithm or calls made on suboptimal alignments (Additional file 2: Figure S2b). The 
low precision led us to manually examine all variants to ensure an accurate collection was 
used for downstream analysis. 
In the second part of the analyses, we ascertained the sensitivity of our algorithm on the 
zebrafish melanoma dataset by comparing the CaVEMan calls for one sample (ZD8a) to 
those from SomaticSniper [21] and String Graph Assembler (SGA) [22]. Our results showed 
that SomaticSniper, and not SGA, provided a 10% increase of somatic variants to the 
CaVEMan algorithm (Additional file 2: Figure S2c-e). In spite of this marginal increase, we 
added a subset of non-overlapping Sniper variants to the CaVEMan calls, which we 
experimentally validated through targeted enrichment and Illumina sequencing (Additional 
file 2: Figure S3). All calls from this analysis were then subject to a second, manual review. 
Overview of substitutions and indels in engineered zebrafish melanomas 
We confirmed a total of 403 point mutations and 13 insertions and deletions (indels), the 
latter of which were identified using Pindel [23] and processed using similar method to the 
substitutions (Figure 2a). Of the substitutions, 79 were synonymous, 168 resulted in amino 
acid changes, 16 were nonsense and 25 occurred at splice sites (Additional file 1: Table S3). 
Eighty-five substitutions were found in the 3'UTR and 26 in the 5'UTR, and one start codon 
was gained. The ratio of 2.3:1 non synonymous to synonymous events was similar to the 
averages previously reported in human melanoma [9,10]. The median number of coding 
mutations per sample was four, significantly fewer than the median of 171 in sun-exposed 
human melanomas and closer to the median of nine in mucosal and uveal melanomas, also 
originating from sun-shielded sites [9]. Over half of the total number of mutations in the 
study set was present in only eight samples (15%), six of which had two or fewer engineered 
“initiating drivers”. The highest number of substitutions were found in samples with one or 
two initiating drivers: ZD0038a (BRAF), ZD24a (NRAS), ZD23a (NRAS;p53+/-) and ZD30a 
(NRAS;p53-/-). 
Figure 2 Overview of substitutions. A) The number of substitutions (dark blue columns) 
and indels (red columns) per sample, corresponding to their initiating germline mutations 
(bottom shaded). For p53, light blue indicates p53+/- and dark blue p53-/-. Asterisk (*) 
specifies mitfa:MITF expression in a mitfa-/- background. B-E) Mutation spectrum of all and 
selected samples. For all samples (B) mutations are indicated on the transcribed (T) and 
untranscribed (UT) strand. F) Evidence of kataegis within 4,500 bp region in ZD8a, a 
BRAF;p53 mutant sample. Somatic mutations are highlighted with coloured circles 
corresponding to the type of substitution. 
Consistent with the low substitution burden, there were few recurrent mutations. Two 
substitutions were found in ttna and ttnb, the two largest protein-coding genes in the 
zebrafish genome. No recurrent substitutions were found in known melanoma genes or genes 
in the Cancer Gene Census [24]. Over 60% of genes mutated in this study were found to be 
mutated at least once in human melanoma [9-11,25-27], which was unsurprising given the 
extensive mutation load in the human disease. Substitutions with predicted coding changes in 
known census cancer genes included a nonsense mutation in ikzf and missense mutations in 
nup214 and pik3cd, while a homozygous missense substitution in the anaphase promoting 
complex gene, anapc1, was identified in a BRAF, p53+/- tumour (ZD8a). 
UV-independent mutation spectra and mutational processes 
Intriguingly, recent studies have shown that over half of the driver mutations in human 
melanomas do not bear the UV radiation associated signature [10]. To explore the nature of 
the non-UV events, we examined the mutation spectrum in the engineered zebrafish 
melanomas developed under conditions without detectable UV light, as determined using a 
standard laboratory photometer (International Light 1400). As with most human cancers, C > 
T substitutions (24.4%) constituted the prominent mutation class across all samples, 
including ZD8a and ZD24a (Figure 2c-d), which had substantial mutation burdens. 
Remarkably, ZD0038a, which had the highest substitution load (n = 47), consisted of 
mutations occurring exclusively at cytosine or guanine residues (Figure 2e), a mutation 
signature that has not yet been described in human cancers. In this sample, all coding 
substitutions apart from one resulted in a predicted missense (n = 21) or a nonsense change (n 
= 3). To determine if this was the result of positive selection, we calculated the dN/dS ratio 
using a mutation-selection model. We found that the rates of missense and nonsense 
mutations for this sample were ~5.5 and ~9.8 times higher than expected by neutral 
evolution, respectively, a result unlikely in the absence of positive selection (PdM/dS = 0.030 
and PdNS/dS = 0.031). 
Similar to findings in non-sun exposed human melanomas [9], no significant bias of 
mutations was found in any class on any particular strand (Figure 2b). By comparison, a 
mutation strand-bias caused by transcription-coupled repair has been demonstrated in UV 
light induced melanomas, lung and breast cancers, all of which display the characteristic 
signatures of their respective UV, tobacco and DNA repair mutagens [9,28,29]. The absence 
of this signature in our samples suggests that these repair processes are not overt unless 
triggered by a selective, mutagenic pressure. 
ZD8a, a BRAF and p53 mutant, presented two microclusters of mutations. Twelve 
substitutions (40% of the total load) spanned exons within a 4,500 base pair (bp) interval of 
the hoxd9a and hoxd10a genes (Figure 2f), while a second cluster of five mutations was 
found within a 5 kb interval (Additional file 2: Figure S4). These microclusters were 
reminiscent of “kataegis”, hypermutated regions resulting from a single event [30]. A close 
examination of the reads revealed that the substitutions occurred in cis, had similar variant 
allele fractions and were mostly C > T transitions (n = 12/26) (Figure 2f). In human, patterns 
of kataegis have been proposed to be related to mutational processes of the AID/APOBEC 
family of enzymes, which modulates antibody diversification by deaminating cytidines to 
deoxyuridine within immunoglobulin genes [30,31]. Although APOBEC emerged only in 
primates, they are believed to have derived from the functionally conserved AID enzymes 
[32], which may provide the mechanistic origin of these clusters in zebrafish. 
Insertions and deletions 
Indels were sparse, with a total of 13 confirmed indels across the 53 samples (Additional file 
1: Table S4). This is lower than the sample average of two to four indels in human melanoma 
[9]. Eight indels were single-base pair indels, and all 13 (<5 bp) were flanked by tandem 
repeat sequences on either side, evidence of a lapse in post-replicative mismatch repair found 
commonly in breast cancer genomes [30]. Ten indels were out of frame and likely to cause 
loss of gene function. Four indels (36%) were found in a sample mutant only in BRAF 
(ZD0038). Interestingly, a single nucleotide deletion resulting in a frameshift mutation was 
found in pik3ip1 (V170fs*), which in human directly binds to the p110 catalytic subunit of 
PIK3 and negatively modulates its activity [33]. Its occurrence in a BRAF, mitfa-/-, p53-/- 
mutant sample is consistent with a role for PI3K cooperation with MAPK deregulation in 
human melanoma [34]. 
Overview of copynumber changes 
In total, 991 amplification segments (copy number > = 5 for samples with ploidy < 2.7, and 
copy number > = 8 for samples with ploidy > = 2.7) and 436 segments of homozygous 
deletions (copy number = 0) were identified by ASCAT [35]. There was marked variation in 
the number of copy number changes among samples in the study set, with a cumulative 5 Gb 
of losses or gains manifesting in over half of tumours analyzed. For samples represented by 
both aCGH and ASCAT data, the frequency recurrence profiles of copy number changes 
from ASCAT generally agreed with those from aCGH performed on the same DNA stock 
(Additional file 2: Figure S5). 
While the majority of samples (85%) harboured at least one amplification, only 30% of the 
samples showed any homozygous deletions (Additional file 1: Table S5). It is therefore worth 
noting that BRAF driven tumours mutant in mitfavc7 had significantly more homozygous 
deletions than expected by chance (P = 0.01 by Chi-Square test, Figure 3b). NRAS subtypes, 
by contrast, did not reveal apparent commonalities (Figure 3a). Clustering of ASCAT and 
aCGH segments from all samples also did not reveal any regions of subgroup affiliation apart 
from the strong amplified signal on chromosomes 18 and 19 (Additional file 2: Figure S6), 
the latter of which is believed to be associated with the BRAFV600E transgene integration as a 
concatemer on chromosome 19. 
Figure 3 Identification of a frequently amplified locus on chromosome 3. Frequency 
profiles of tumours mutant in A) NRAS;p53-/-;X, B) BRAF;mitfavc7;X tumours and C) 
BRAF;p53;mitfa-/-;mitfa:MITF;mitfa:X, where X can include additional drivers as mentioned 
in the text. D) Amplification segments supporting a peak on chromosome 3 in tumours of 
BRAF;p53;mitfa-/-;mitfa:MITF;mitfa:X background derived from exome sequencing (maroon 
segments) and aCGH (green dotted segments). Samples mutated are represented by inverted, 
colour-coded triangles above the corresponding gene indicated by the thick black bar. E) 
Frequently amplified genes in the entire dataset. F) Number of copies (Y-axis) of the genes 
(X-axis) in the region of amplified locus. Each line represents a tumour that is colour-coded 
according to either BRAF;p53;mitfa-/-;mitfa:MITF;mitfa:X (yellow) or other (blue) 
background status. The most frequently amplified genes are highlighted in yellow for in 
Figures D-F. 
Identification of a recurrently amplified region in a subset of zebrafish 
melanomas 
A particularly striking finding was the recurrence of a 175 kb amplicon on chromosome 3 
(50.0 to 51.2 Mb) in 10 tumours belonging to the BRAF, p53-/-, mitfa-/- background with 
MITF rescue (Figure 3c). Although this subgroup is the largest of our dataset (47%, 25/53), 
the clustering of the recurrent amplicon in this subgroup was unlikely to have occurred by 
chance (P = 0.000256 by Chi-Square Test). Amplified segments were supported by both 
ASCAT and aCGH (Figure 3d). The most frequently amplified genes were prkacaa and 
samd1 (1 of 2) presenting in 10/53 samples, followed by as1ba (n = 9), wu:fj41e11 (n = 9) 
and tecra (n = 8) (Figure 3e). While amplifications were found across all 10 samples for 
samd1 and prkacaa, they presented in five or fewer samples for flanking genes RNF222 and 
gcgr (Figure 3d). 
A simulation was performed to determine the likelihood of the events occurring in these 
genes, at this frequency, by chance. For each sample, the number and lengths of the amplified 
segments were randomly introduced across the target exome regions one million times, 
producing a P-value that was adjusted by Bonferroni correction (n = 6,677). We did not 
factor causes of amplification other than those by chance, such as nearby fragile sites, for 
which little information is available for zebrafish. 
Based on our simulations, all genes recurrently amplified in six or more samples were likely 
to be significant, including prkacaa, samd1, asf1ba, wu:fj41e11 and tecra (n = 13, Additional 
file 1: Table S6). These genes did not show evidence of amplification or overexpression in 
human cancer datasets (CCLE, Oncomine, COSMIC) or large, comprehensive melanoma 
studies [9,10]. Genes recurrently amplified in fewer samples also showed significant 
enrichment (P = < 0.05, Additional file 1: Table S6). Among these, interestingly, was tert (P 
= 0.0, n = 4 samples), which encodes the reverse transcriptase subunit of telomerase 
responsible for maintaining the ends of chromosomes. Tert was the only known cancer gene 
recurrently mutated in our study set. In human melanoma, TERT is amplified [10,36] and 
harbours promoter mutations in as many as 90% of melanoma cases [7,8]. 
Identification of few recurrent homozygous deletions 
A total of 366 deletion events were identified, affecting the same genes in at most three 
samples in the study set (Figure 4a). By performing the above simulations, we determined the 
majority (28/30) of genes deleted in three samples were unexpected by chance (Additional 
file 1: Table S7). The genes nitr1i, nitr3a, nitr7b and nitr7a were in a locus deleted in three 
samples belonging to both BRAF and NRAS mutant lines (Figure 4b). The nitr genes are 
members of a highly diversified, multigene family of novel immune type receptor found in 
teleosts. Nitr genes do not rearrange like immune receptors but show structural similarities to 
both the mammalian T-cell or Ig-like receptors [37,38]. Loss of these genes could be relevant 
to one facet of progression which is to avoid immune surveillance, consistent with a critical 
role of immune regulation in human melanoma [39]. Other recurrently deleted genes include 
sema6d, plcd3a, mrps5, cyp2y3 and xirp (Figure 4c-h), none of which had been previously 
implicated in human cancer. Further investigation would provide insights into the 
contribution of these genes to tumourigenesis in zebrafish. 
Figure 4 Overview of homozygous deletions. A) Frequency of homozygously deleted genes 
across samples. B) Recurrently deleted loci occurring in at least three samples that are driven 
by BRAF (dark blue) or NRAS (light blue), and the corresponding genes in these regions 
(right hand side). C) Examples of deleted segments (dark blue bars) and the genes in these 
regions (bottom labelled), represented by their exon structures (dark blue lines). 
Relationships between age, drivers, and mutation burden 
We exploited the model system to explore the footprints of mutagenesis assuming a uniform 
basal mutational clock. Where data for the age of fish (at tumour collection) was available, 
we found a significant correlation between age and the number of substitutions using the 
Pearson’s Correlation test and a Generalized Linear Model (R = 0.37, P = 0.02, GLM P = 
0.0035). Positive correlations have similarly been found in human melanoma [9]. Age of 
onset and number of drivers were themselves strongly negatively correlated. If each germline 
driver was counted as one event in a requisite multistep process, we could attempt to 
delineate a relationship between these initiating events and extent of the mutations. For 
transgenic zebrafish of the genotype BRAFV600E;p53-/-;mitfa-/-;mitfa:MITF, a value of four 
drivers were assigned, due to the yet unknown contributions of the additional genes 
(KROX20, FOXD3, OCT6) to melanoma. Interestingly, our data showed a significant, inverse 
association between the number of drivers and the substitution events (R = -0.45, P = 
0.00075, GLM P = 0.00031), indicating that a greater number of drivers require fewer 
additional events to generate the melanoma lesions. To determine if this correlation extended 
to copy number events, we considered each amplified or deleted segment as an event in the 
tumour. Our data showed that if we considered drivers and age together, this was also a 
significant predictor of the total number of copy number events (GLM P = 0.00011, 
Additional file 1: Table S8). 
Functional categorization of frequently mutated genes 
Similar to human cancers, the engineered melanomas overall displayed high heterogeneity, 
where the majority of genes mutated in only one sample (68%) (Additional file 2: Figure 
S7a). Taking into account all the different modalities of mutation and their frequencies of 
occurrence, a P-value was calculated (using a binomial test) for each mutated gene 
(Additional file 1: Table S9). Due to the high frequency of recurrence, prkacaa and samd1 
presented with the highest significance (P = 2.31 X 10-8). Following this, we explored the 
potential functional themes underlying these aberrations through a KEGG pathway analysis, 
which revealed that the enrichment for most pathways declines when the minimum threshold 
for number of mutated samples is raised (Additional file 2: Figure S7b). From this we infer 
that although many genes are not frequently mutated and significant by themselves (i.e. 
mutated only once), the pathways in which they reside are significantly mutated. Among the 
enriched pathways in this study (Additional file 1: Table S10), two include biological 
processes that have been directly linked to the hallmarks of cancer (apoptosis and VEGF 
signaling, for angiogenesis), while deregulation of two other pathways, p53 signaling and 
melanogenesis (Additional file 2: Figure S7c), have previously been implicated in melanoma 
[40]. Also showing significant enrichment was the MAPK signaling and cell cycle pathway, 
thus further supporting functions important in human melanoma development. 
Conclusions 
We have provided a comprehensive overview of the genetic events in engineered zebrafish 
models harbouring known driver alleles. Several new insights into the mutagenic processes in 
non UV-mediated, engineered melanomas, and the biology of BRAF and NRAS-driven 
malignancies, can be drawn from these 53 exomes. 
Our results show that in the absence of direct UV light, engineered melanomas develop 
similar mutational signatures to most human cancers, dominated by the evolutionary 
conserved spontaneous deamination of cytosine to thymidine [9]. We also found rare cases 
exhibiting remarkably distinct mutation spectra, including indications of kataegis and a novel, 
unclassified mutational signature. 
Importantly, our results demonstrate that tumours driven primarily by a greater number of 
known cancer genes typically manifest with fewer mutations, suggesting that such models 
can be used to bound and estimate the number of events in human cancers. Mouse models of 
acute myeloid leukemia and mammary tumours similarly displayed fewer mutations and 
structural rearrangements, respectively, than their human counterparts [41,42]. It could be 
speculated that predisposed human individuals would support the same conclusion. With 
nearly half of the samples presenting no substitutions or indels, however, these two classes of 
mutations are unlikely to be the only route to the additional mutations needed for full 
melanoma development, with potentially other factors such as chromatin modifications at 
play. 
The highly recurrent amplicon in transgenic lines with BRAF;p53;mitfa-/-;mitfa:MITF 
encompassing the genes, prkacaa, samd1, tecra, wu:fj41e11 and asf1b, indicates a strong 
selection for genes in this interval in mutant BRAF, p53 and mitfa lines with MITF rescue. 
Although the amplicon was exclusive to the BRAF;p53;mitfa-/-;mitfa:MITF transgenic 
models, it is unclear whether it would also present in the BRAF or BRAF;p53 mutant models 
given a larger sample cohort. Since MITF serves as a functional rescue in this transgenic line, 
the genetics of this subset may be comparable to human tumours that show dependency on 
MITF for growth, either through MITF amplification or over expression. That none of the 
genes in this amplicon have been reported so far as mutated in human melanoma could 
therefore be due to its specific occurrence with BRAF, p53 and amplified MITF, found in less 
than 5% of BRAF mutant metastatic melanomas and a rare combination (Additional file 2: 
Figure S8). 
In this amplicon, amplification of prkacaa, which encodes one of two principal catalytic (C) 
subunits of protein kinase A (pka), is intriguing for several reasons. Human PRKACA is the 
principle catalytic subunit of protein kinase A (PKA) [43]. Although not previously 
associated with melanoma, the cAMP-PKA pathway is a major signal transduction pathway 
for melanin production, melanocyte proliferation and differentiation (reviewed in [44]) and 
has been implicated in pituitary tumourigenesis [45,46]. Mutations in PRKAR1A, a PKA-
regulatory subunit, cause an inherited syndrome called the Carney complex, characterized by 
pigmented skin lesions, schwannomas, recurrent mucocutaneous myxomas and endocrine 
neoplasms [47,48]. Indeed, cAMP-dependent PKA activation has been shown to result in the 
upregulation of the mitfa promoter, tyrosinase expression and melanin synthesis, affecting 
skin pigmentation and melanogenesis [49]. Of interest, recent data has interestingly 
demonstrated a link between pigment production and UV-independent melanomagenesis, 
where harmful accumulation of pheomelanin intermediates or by-products during pigment 
synthesis can promote tumour formation [40]. Thus, a potential consequence of PRKACA 
amplification may be disruption of PKA signaling and pigment production, pointing to its 
possible contribution to aberrant pigment production in UV-independent carcinogenesis. 
An important observation of this study is that, apart from the amplicon, the BRAF and NRAS 
driven melanomas display striking genetic heterogeneity similar to human cancers and mouse 
cancer models [41,42]. One interpretation of this finding is that tumourigenic processes are 
achieved through the contribution of many different mutated genes, in line with previous 
findings in mice cooperativity screens [50] and low frequency drivers unveiled from 
emerging studies of human melanoma [9-11]. The enrichment of mutations in pathways 
known to be important for melanoma development, such as MAPK and p53 signaling, in the 
presence of germline mutations affecting BRAF, NRAS and p53, also suggest that further 
modulation of these pathway signaling is required for full manifestation of the tumours. 
To the best of our knowledge, the spectrum of somatic coding mutations in an engineered 
model of melanoma has not yet been described. The integrated analysis we report here thus 
provides a glimpse into the genetic paths to BRAF and NRAS-driven tumourigenesis, 
providing a framework for genomic characterization, and a standard for evaluating and 
prosecuting detailed biological questions in engineered animal models of cancer. 
Materials and methods 
Simulation of zebrafish cancer genomes 
Individual zebrafish genomes were created with a SNP density of 0, 0.001, 0.01, 0.1, and 0.5 
SNPs/base by randomly generating substitutions across the genome using an in-house 
simulation script. Using each individual genome, referred to as the “normal”, we created a 
second genome containing an additional 2,000 substitutions for the “tumour”. For each 
normal and tumour genome, we simulated 75 bp reads in FASTQ format using wgsim [51], 
specifying null for the base mutation rate, error rate and indel mutation rate. To simulate 
normal contamination, we combined normal and tumour FASTQ files for each individual 
according to the following proportions to obtain an average sequencing coverage of 80X 
(Table 2). 
Table 2 Metrics for simulating normal contamination in tumour and normal genome 
FASTA files 
SNP density Type 
Millions of reads 
Normal Tumour content 30% 60% 100% 
0 Normal 8 5.6 3.2 0 
 Tumour 0 2.4 4.8 8 
0.001 Normal 8 5.6 3.2 0 
 Tumour 0 2.4 4.8 8 
0.01 Normal 8 5.6 3.2 0 
 Tumour 0 2.4 4.8 8 
0.1 Normal 8 5.6 3.2 0 
 Tumour 0 2.4 4.8 8 
0.5 Normal 8 5.6 3.2 0 
 Tumour 0 2.4 4.8 8 
The simulated tumour and normal pairs were subsequently processed through the Cancer 
Genome Project Sequencing Pipeline. 
Sample collection 
Zebrafish tumour and normal tissue samples were obtained from Amy Capper and Jennifer 
Richardson (Elizabeth Patton's lab, University of Edinburgh, Edinburgh, UK), and from 
Richard White and Charles Kaufman (Len Zon's lab, Boston Children's Hospital, Boston). All 
samples were obtained in accordance with the UK Home Office regulations, UK Animals 
(Scientific Procedures) Act 1986, and reviewed by the Wellcome Trust Sanger Institute 
Ethical Review Committee. Samples from Elizabeth Patton's lab were subject to 
histopathological review by a clinical pathologist (Marie Mathers, Edinburgh Western 
General Hospital). We were unable to perform histopathology on samples from Len Zon’s 
lab. Normal tissue included sections from the fin, head, or gut. Zebrafish melanoma and 
normal DNA were extracted from fresh frozen tissues using the Qiagen Blood and Tissue 
DNAeasy Kit (Cat # 69504). Melanomas were derived from transgenic zebrafish expressing 
either the BRAFV600E or NRASQ61K human oncogene as previously described [5,6,18]. 
Exome bait set 
Exon sequences for bait set design were initially downloaded from BioMart [52] to 
encompass all protein coding genes, 3’UTR and 5’UTR regions from Ensembl 58 of the Zv8 
genome. The bait set was subsequently adjusted to encompass additional genes from Ensembl 
61 and new releases of the Zv9 genome (Zebrafish Agilent All Exon SureSelect). A total of 
2,309 Gb of sequencing was generated, averaging approximately 21.8 Gb per sample, of 
which 79.6% of reads mapped and 55% of which mapped to target coding regions (i.e. “on 
target”) (Additional file 1: Table S2). By comparison to the human exome [20], the 
performance of the zebrafish exome was slightly lower (in human, 89% of reads map, 
averaging 62% on target coverage), requiring a greater total sequencing depth to acquire the 
desired baseline coverage of 20X. 
DNA and library preparation, capture and sequencing 
DNA libraries were prepared using the Illumina Paired End Sample Prep Kit according to the 
manufacturer’s protocol. For targeted enrichment, in the first iteration, we designed a custom 
bait set to target the zebrafish exome for solution capture to include all the exons of all 
protein coding genes in the Zv8 Ensembl 58 gene build. Subsequently, an additional 2,059 
genes were added to include improved annotations in the Zv9 assembly and Ensembl 59 gene 
build. Targeted enrichment was performed as described [53] following the manufacturer’s 
instructions. 
Sequencing with 75 base paired-end reads of targeted-enrichment libraries was performed on 
the Illumina GAIIx and the HiSeq 2000 sequencers. Reads were mapped to the zebrafish 
reference (Zv9 Ensembl 61) using the Burrows-Wheeler Algorithm (BWA version 0.5.9) [54] 
under default parameters and excluding library PCR duplicates. 
Identification of substitutions variants 
CaVEMan 
CaVEMan (cancer variants through expectation maximization), an in-house algorithm, was 
employed to call single nucleotide substitutions in our dataset. Post-processing filters 
developed for human variant calling and additional filters were applied to the set of initial 
CaVEMan mutation calls to improve the specificity of the output. 
SomaticSniper 
Tumour and normal BAM files were processed by SomaticSniper [21] with a specification 
for read and base quality of at least 40. Raw variants were post-processed using scripts 
obtained through Github [55], modified to include a variant allele frequency of no more than 
3% in the normal sample and less than 10% of the tumour, and without germline SNPs or 
indels within 5 bp of any of the normal zebrafish exomes. Variants were annotated using the 
Ensembl variant effect predictor (Ensembl 64 gene build) specifying only coding variants as 
output. 
SGA 
SGA analysis was run by Jared Simpson using a modified algorithm [22]. 
Identification of insertions and deletions 
Insertions and deletions were called using a modified version of Pindel [23] as previously 
described [28]. To improve the identification of high confidence variants, we specified a 
requirement for a minimum depth of 15 reads in both tumour and normal samples. For small 
indels, at least four reads supporting the variant seen by Pindel and at least one by BWA were 
required. Larger indels were defined in non-repeat regions where the mutation was seen once 
on either strand by Pindel. All indels were manually reviewed for confirmation. 
Variant validation 
Capillary and 454 resequencing 
Validation of substitutions and indel variants was initially attempted through capillary or 454 
Roche resequencing of amplified PCR products spanning the mutation in the tumour and the 
normal DNA, which had been subject to whole-genome amplification from the original stock 
using GenomiPhi (illustra GenomiPhi HY DNA Amplification Kit, Cat# 25-6600-20), 
according to the manufacturer's instructions. Nested PCR improved PCR yield over a single 
round of amplification, but both capillary and 454 Roche approaches proved problematic in 
PCR-amplified zebrafish DNA. 
Targeted capture and illumina sequencing 
To circumvent problems with PCR-based validation, we designed a custom bait set targeting 
the mutant alleles for enrichment followed by Illumina sequencing. We streamlined the 
validation study set by qualitatively reviewing each variant and keeping only CaVEMAN 
calls that did not show germline mutations and were supported by high quality mapping reads 
and alignment. An additional 1,700 non-overlapping, Sniper variants (60% of the total non-
overlapping Sniper calls) were selected at random to include in the validation set, comprising 
a bait set of 1.4 MB with minimal tiling probes flanking 60 bp on either side of each variant. 
DNA libraries were made as described above and pooled into eight samples per group with 
barcode identifiers. Targeted capture was performed with each pool according to 
manufacturer's instructions followed by 100 bp paired-end sequencing on the Illumina HiSeq 
2000 and default BWA alignment. Mutant variants were confirmed on Samtools Pileup files 
using a separate, in-house validation script based on tumour and normal allele depth and 
quality. All confirmed variants were subjected to an additional, manual review. 
Identification of copy number variants 
Copy number variation was determined primarily through ASCAT [35]. Only segments under 
10 MB in length were considered. Genes falling in these segment regions were annotated 
using the Ensembl variant effect predictor (Ensembl 64). Segment data was analyzed using R, 
Nexus Copy Number Software 6.1 (Biodiscovery, [56]), visualized using IGV [57,58] and 
plotted using Progenetix [59]. 
Array CGH 
Array CGH (aCGH) was performed on a subset of 24 zebrafish melanoma normal and 
tumour samples using a Nimblegen Custom Design 12 × 135 K CGH Array (Roche 
Nimblegen Technologies, Cat #05223881001) containing 135,000 probes covering the length 
of the zebrafish Zv9 genome. In brief, tumour and normal DNA were labeled, competitively 
hybridized to the array for 48 hours, washed and scanned using a 5 micron scanner 
(Molecular Devices). Signal intensities were extracted using the DEVA v1.2.1 Software 
(Nimblegen, [60]). Overall data quality was evaluated as recommended in the DEVA 
Software User's Guide [61]. Segmentation was performed using the R Copynumber Package 
[62] and visualized using the Nexus Copy Number Software (6.1) (Biodiscovery), IGV 
[57,58] and Progenetix [59]. 
Statistical analyses 
Codon selection 
We used the method described in [63] to evaluate whether amino acid changes in ZD0038a 
occurred at a higher frequency than expected in the absence of positive selection. Briefly, we 
used 12 parameters to describe the different rates of the 12 possible single nucleotide 
substitutions, and two parameters (analogous to dN/dS) to describe selection at missense and 
nonsense mutations. This allowed us to quantify the strength of the selection without the 
confounding effect of sequence composition and different rates of each substitution type. 
Maximum-likelihood was used to estimate these parameters and Likelihood Ratio Tests were 
used to test deviations from neutrality (dN/dS = 1). Analogous results to those presented in 
the main text were obtained using the traditional codon model approach used in phylogenetic 
analyses (implemented in [64]) as well as accounting for CpG context-dependent effects. 
Estimation of the number of mutated copies 
Allele-specific copy number estimates for point mutations were obtained by integrating copy 
number and sequencing data as described in [35]. 
Simulations of amplifications and homozygous deletions 
Simulations were performed as described in [65] (in preparation). 
Evaluation of driver and age correlation 
Mutation burden and driver correlation was performed as previously described [20]. 
Pathway analysis 
Mutation significance analysis 
We combined mutation data from substitutions, insertions and deletions, and copy number 
changes (amplifications and homozygous deletions) to assess the likelihood of a gene being 
mutated in more samples than expected by chance. As each mutation type can occur at a 
different frequency (where amplifications are more frequent than deletions), each mutation 
type was considered separately. Thus, to calculate a combined P-value for each gene j, we 
used the following Equation 1: 
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with N number of genes in the genome. 
Entrez gene mapping 
For compatibility with the KEGG database, we mapped Danio rerio Ensembl IDs onto Entrez 
IDs using NCBI [66], which includes a cross-reference of Entrez to Ensembl. Target genes 
that could not be matched in this fashion were matched using gene symbol and synonyms. 
Pathway analysis 
We used knowledge from the KEGG database to construct a large protein interaction 
network. To gauge whether a pathway contains more frequently mutated genes than expected 
by chance, a KEGG pathway enrichment was performed for all 215 pathways in the Danio 
rerio specific KEGG database. 
All genes with a combined P-value < 0.05 (as calculated according to the Mutation 
Significance Analysis) were selected for the pathway analysis. This cutoff selected for genes 
with at least two amplifications, and given rarer mutation types, genes with at least one 
mutation other than an amplification. 
We called a gene frequently mutated if it carried at least N mutations, where N can be 
between one and 10 (Additional file 1: Table S9). Genes with mutation counts of three or 
more were visualized in the context of their KEGG pathway interactions using Cytoscape 
[67]. 
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